100% survival in clinical test puts Rocket Pharma gene therapy on course to FDA May 20, 2022 Auto Bot BioPharma, Clinical Trial, gene therapy, New Jersey, Pharma, Rare diseases 0 A Rocket Pharmaceuticals gene therapy for the rare immune disorder leukocyte adhesion deficiency-I has met the survival goals of a pivotal study, paving the way for regulatory submissions that the company expects to file in early 2023.